Sample | Title | Value | Rank |
GSM1256968 | SLE-patients; Group 3: CD16pos, resident monocytes; active SLE 1 | 96.2769 | 78 |
GSM1256969 | SLE-patients; Group 3: CD16pos, resident monocytes; active SLE 2 | 79.1376 | 75 |
GSM1256970 | SLE-patients; Group 3: CD16pos, resident monocytes; active SLE 3 | 110.217 | 79 |
GSM1256971 | SLE-patients; Group 3: CD16pos, resident monocytes; active SLE 4 | 149.09 | 82 |
GSM1256988 | Yellow fever vaccinated NDs; Group 8: CD16pos, resident monocytes; ND 55 before YFV | 206.966 | 85 |
GSM1256991 | Yellow fever vaccinated NDs; Group 9: CD16pos, resident monocytes; ND 55 seven days after YFV | 225.995 | 86 |
GSM1256989 | Yellow fever vaccinated NDs; Group 8: CD16pos, resident monocytes; ND 56 before YFV | 189.351 | 85 |
GSM1256992 | Yellow fever vaccinated NDs; Group 9: CD16pos, resident monocytes; ND 56 seven days after YFV | 155.092 | 83 |
GSM1256990 | Yellow fever vaccinated NDs; Group 8: CD16pos, resident monocytes; ND 57 before YFV | 222.277 | 86 |
GSM1256993 | Yellow fever vaccinated NDs; Group 9: CD16pos, resident monocytes; ND 57 seven days after YFV | 212.017 | 86 |